Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Identifieur interne : 000403 ( PubMed/Corpus ); précédent : 000402; suivant : 000404Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Auteurs : Javier Castro-Hernández ; Domingo Afonso-Oramas ; Ignacio Cruz-Muros ; Josmar Salas-Hernández ; Pedro Barroso-Chinea ; Rosario Moratalla ; Mark J. Millan ; Tomás González-HernándezSource :
- Neurobiology of disease [ 1095-953X ] ; 2015.
English descriptors
- KwdEn :
- Animals, Antidepressive Agents (pharmacology), Antiparkinson Agents (pharmacology), Autoreceptors (metabolism), Benzothiazoles (pharmacology), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Dimerization, Dopamine (metabolism), Dopamine Agonists (pharmacology), Dopamine Plasma Membrane Transport Proteins (metabolism), Male, Mice, Inbred C57BL, Mice, Knockout, Receptors, Dopamine D3 (agonists), Receptors, Dopamine D3 (genetics), Receptors, Dopamine D3 (metabolism), alpha-Synuclein (metabolism).
- MESH :
- chemical , agonists : Receptors, Dopamine D3.
- chemical , genetics : Receptors, Dopamine D3.
- chemical , metabolism : Autoreceptors, Dopamine, Dopamine Plasma Membrane Transport Proteins, Receptors, Dopamine D3, alpha-Synuclein.
- chemical , pharmacology : Antidepressive Agents, Antiparkinson Agents, Benzothiazoles, Dopamine Agonists.
- drug effects : Corpus Striatum.
- metabolism : Corpus Striatum.
- Animals, Dimerization, Male, Mice, Inbred C57BL, Mice, Knockout.
Abstract
The dopamine (DA) transporter (DAT), a membrane glycoprotein expressed in dopaminergic neurons, clears DA from extracellular space and is regulated by diverse presynaptic proteins like protein kinases, α-synuclein, D2 and D3 autoreceptors. DAT dysfunction is implicated in Parkinson's disease and depression, which are therapeutically treated by dopaminergic D2/D3 receptor (D2/D3R) agonists. It is, then, important to improve our understanding of interactions between D3R and DAT. We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution. The effect of pramipexole was absent in mice with genetically-deleted D3R (D3R(-/-)), yet unaffected in mice genetically deprived of D2R (D2R(-/-)). Pramipexole treatment induced a physical interaction between D3R and DAT, as assessed by co-immunoprecipitation and in situ proximity ligation assay. Furthermore, it promoted the formation of DAT dimers and DAT association with both D2R and α-synuclein, effects that were abolished in D3R(-/-) mice, yet unaffected in D2R(-/-) mice, indicating dependence upon D3R. Collectively, these data suggest that prolonged treatment with dopaminergic D3 agonists provokes a reduction in DA reuptake by dopaminergic neurons related to a hitherto-unsuspected modification of the DAT interactome. These observations provide novel insights into the long-term antiparkinson, antidepressant and additional clinical actions of pramipexole and other D3R agonists.
DOI: 10.1016/j.nbd.2014.12.007
PubMed: 25511804
Links to Exploration step
pubmed:25511804Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.</title><author><name sortKey="Castro Hernandez, Javier" sort="Castro Hernandez, Javier" uniqKey="Castro Hernandez J" first="Javier" last="Castro-Hernández">Javier Castro-Hernández</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Afonso Oramas, Domingo" sort="Afonso Oramas, Domingo" uniqKey="Afonso Oramas D" first="Domingo" last="Afonso-Oramas">Domingo Afonso-Oramas</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Cruz Muros, Ignacio" sort="Cruz Muros, Ignacio" uniqKey="Cruz Muros I" first="Ignacio" last="Cruz-Muros">Ignacio Cruz-Muros</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Salas Hernandez, Josmar" sort="Salas Hernandez, Josmar" uniqKey="Salas Hernandez J" first="Josmar" last="Salas-Hernández">Josmar Salas-Hernández</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Barroso Chinea, Pedro" sort="Barroso Chinea, Pedro" uniqKey="Barroso Chinea P" first="Pedro" last="Barroso-Chinea">Pedro Barroso-Chinea</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Moratalla, Rosario" sort="Moratalla, Rosario" uniqKey="Moratalla R" first="Rosario" last="Moratalla">Rosario Moratalla</name><affiliation><nlm:affiliation>Departamento de Biología Funcional y de Sistemas, Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain; Centro de investigación Biomédica en Red sobre enfermedades neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J" last="Millan">Mark J. Millan</name><affiliation><nlm:affiliation>Pole of Innovation in Neuropsychopharmacology, Institut de Recherches Servier, 78290 Croissy sur Seine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez Hernandez, Tomas" sort="Gonzalez Hernandez, Tomas" uniqKey="Gonzalez Hernandez T" first="Tomás" last="González-Hernández">Tomás González-Hernández</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain; Centro de investigación Biomédica en Red sobre enfermedades neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Spain. Electronic address: tgonhern@ull.es.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25511804</idno><idno type="pmid">25511804</idno><idno type="doi">10.1016/j.nbd.2014.12.007</idno><idno type="wicri:Area/PubMed/Corpus">000403</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000403</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.</title><author><name sortKey="Castro Hernandez, Javier" sort="Castro Hernandez, Javier" uniqKey="Castro Hernandez J" first="Javier" last="Castro-Hernández">Javier Castro-Hernández</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Afonso Oramas, Domingo" sort="Afonso Oramas, Domingo" uniqKey="Afonso Oramas D" first="Domingo" last="Afonso-Oramas">Domingo Afonso-Oramas</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Cruz Muros, Ignacio" sort="Cruz Muros, Ignacio" uniqKey="Cruz Muros I" first="Ignacio" last="Cruz-Muros">Ignacio Cruz-Muros</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Salas Hernandez, Josmar" sort="Salas Hernandez, Josmar" uniqKey="Salas Hernandez J" first="Josmar" last="Salas-Hernández">Josmar Salas-Hernández</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Barroso Chinea, Pedro" sort="Barroso Chinea, Pedro" uniqKey="Barroso Chinea P" first="Pedro" last="Barroso-Chinea">Pedro Barroso-Chinea</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Moratalla, Rosario" sort="Moratalla, Rosario" uniqKey="Moratalla R" first="Rosario" last="Moratalla">Rosario Moratalla</name><affiliation><nlm:affiliation>Departamento de Biología Funcional y de Sistemas, Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain; Centro de investigación Biomédica en Red sobre enfermedades neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J" last="Millan">Mark J. Millan</name><affiliation><nlm:affiliation>Pole of Innovation in Neuropsychopharmacology, Institut de Recherches Servier, 78290 Croissy sur Seine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez Hernandez, Tomas" sort="Gonzalez Hernandez, Tomas" uniqKey="Gonzalez Hernandez T" first="Tomás" last="González-Hernández">Tomás González-Hernández</name><affiliation><nlm:affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain; Centro de investigación Biomédica en Red sobre enfermedades neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Spain. Electronic address: tgonhern@ull.es.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Neurobiology of disease</title><idno type="eISSN">1095-953X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antidepressive Agents (pharmacology)</term><term>Antiparkinson Agents (pharmacology)</term><term>Autoreceptors (metabolism)</term><term>Benzothiazoles (pharmacology)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Dimerization</term><term>Dopamine (metabolism)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Plasma Membrane Transport Proteins (metabolism)</term><term>Male</term><term>Mice, Inbred C57BL</term><term>Mice, Knockout</term><term>Receptors, Dopamine D3 (agonists)</term><term>Receptors, Dopamine D3 (genetics)</term><term>Receptors, Dopamine D3 (metabolism)</term><term>alpha-Synuclein (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, Dopamine D3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Receptors, Dopamine D3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Autoreceptors</term><term>Dopamine</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Receptors, Dopamine D3</term><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antidepressive Agents</term><term>Antiparkinson Agents</term><term>Benzothiazoles</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dimerization</term><term>Male</term><term>Mice, Inbred C57BL</term><term>Mice, Knockout</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The dopamine (DA) transporter (DAT), a membrane glycoprotein expressed in dopaminergic neurons, clears DA from extracellular space and is regulated by diverse presynaptic proteins like protein kinases, α-synuclein, D2 and D3 autoreceptors. DAT dysfunction is implicated in Parkinson's disease and depression, which are therapeutically treated by dopaminergic D2/D3 receptor (D2/D3R) agonists. It is, then, important to improve our understanding of interactions between D3R and DAT. We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution. The effect of pramipexole was absent in mice with genetically-deleted D3R (D3R(-/-)), yet unaffected in mice genetically deprived of D2R (D2R(-/-)). Pramipexole treatment induced a physical interaction between D3R and DAT, as assessed by co-immunoprecipitation and in situ proximity ligation assay. Furthermore, it promoted the formation of DAT dimers and DAT association with both D2R and α-synuclein, effects that were abolished in D3R(-/-) mice, yet unaffected in D2R(-/-) mice, indicating dependence upon D3R. Collectively, these data suggest that prolonged treatment with dopaminergic D3 agonists provokes a reduction in DA reuptake by dopaminergic neurons related to a hitherto-unsuspected modification of the DAT interactome. These observations provide novel insights into the long-term antiparkinson, antidepressant and additional clinical actions of pramipexole and other D3R agonists.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25511804</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>09</Day></DateCreated><DateCompleted><Year>2016</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol. Dis.</ISOAbbreviation></Journal><ArticleTitle>Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.</ArticleTitle><Pagination><MedlinePgn>325-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2014.12.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(14)00378-7</ELocationID><Abstract><AbstractText>The dopamine (DA) transporter (DAT), a membrane glycoprotein expressed in dopaminergic neurons, clears DA from extracellular space and is regulated by diverse presynaptic proteins like protein kinases, α-synuclein, D2 and D3 autoreceptors. DAT dysfunction is implicated in Parkinson's disease and depression, which are therapeutically treated by dopaminergic D2/D3 receptor (D2/D3R) agonists. It is, then, important to improve our understanding of interactions between D3R and DAT. We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution. The effect of pramipexole was absent in mice with genetically-deleted D3R (D3R(-/-)), yet unaffected in mice genetically deprived of D2R (D2R(-/-)). Pramipexole treatment induced a physical interaction between D3R and DAT, as assessed by co-immunoprecipitation and in situ proximity ligation assay. Furthermore, it promoted the formation of DAT dimers and DAT association with both D2R and α-synuclein, effects that were abolished in D3R(-/-) mice, yet unaffected in D2R(-/-) mice, indicating dependence upon D3R. Collectively, these data suggest that prolonged treatment with dopaminergic D3 agonists provokes a reduction in DA reuptake by dopaminergic neurons related to a hitherto-unsuspected modification of the DAT interactome. These observations provide novel insights into the long-term antiparkinson, antidepressant and additional clinical actions of pramipexole and other D3R agonists.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castro-Hernández</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afonso-Oramas</LastName><ForeName>Domingo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-Muros</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salas-Hernández</LastName><ForeName>Josmar</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barroso-Chinea</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moratalla</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Biología Funcional y de Sistemas, Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain; Centro de investigación Biomédica en Red sobre enfermedades neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millan</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Pole of Innovation in Neuropsychopharmacology, Institut de Recherches Servier, 78290 Croissy sur Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Hernández</LastName><ForeName>Tomás</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departamento de Anatomía, Facultad de Medicina, Instituto de Tecnologías Biomédicas (ITB, CIBICAN), Universidad de La Laguna, Tenerife, Spain; Centro de investigación Biomédica en Red sobre enfermedades neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Spain. Electronic address: tgonhern@ull.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017660">Autoreceptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493594">Drd3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>83619PEU5T</RegistryNumber><NameOfSubstance UI="C061333">pramipexole</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017660" MajorTopicYN="N">Autoreceptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">D(2)R</Keyword><Keyword MajorTopicYN="N">D(3)R</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Dopamine autoreceptor</Keyword><Keyword MajorTopicYN="N">Dopamine transporter</Keyword><Keyword MajorTopicYN="N">Multi-protein complex</Keyword><Keyword MajorTopicYN="N">Neuroprotection</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25511804</ArticleId><ArticleId IdType="pii">S0969-9961(14)00378-7</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2014.12.007</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000403 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000403 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25511804
|texte= Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25511804" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |